MYB and leukemia: We found that our BPDCN MYB fusion–induced mouse leukemias showed sensitivity to ATRA in vitro and in vivo, while CAL1 human BPDCN cells displayed differentiation, cell cycle arrest, and apoptosis upon ATRA treatment in vitro.